Skip to content
Inciteful Med

Biology and Diagnosis: How It Works and How It's Found

Last updated:

Congenital antithrombin deficiency is a genetic disorder caused by a SERPINC1 mutation that increases blood clot risk. Diagnosis involves functional and antigen lab tests, plus genetic sequencing. Taking blood thinners during testing can cause false results, so careful timing is essential.

Key Takeaways

  • • Antithrombin acts as a brake to stop blood from clotting too much, and a deficiency increases your risk of dangerous blood clots.
  • • The condition is caused by mutations in the SERPINC1 gene and is categorized into Type I (low protein amount) and Type II (protein does not work correctly).
  • • Low antithrombin levels can cause heparin resistance, meaning standard heparin blood thinners may not work effectively during a medical emergency.
  • • Accurate diagnosis requires specific blood tests and genetic sequencing, which can be thrown off if you are currently taking blood thinners.

To understand Congenital Antithrombin Deficiency, it helps to think of your blood’s clotting system like a car. Clotting factors (like thrombin) are the “gas” that makes the blood thicken to stop bleeding. Antithrombin is the “brake” that prevents the blood from thickening too much or at the wrong time [1][2].

This condition is caused by a mutation in the SERPINC1 gene, which provides the instructions for making the antithrombin protein [3][4]. When this gene is altered, your “brakes” don’t work as well as they should, leading to an increased risk of blood clots [3].

The Two Types of Deficiency

Doctors categorize this condition into two main types based on what is happening with the antithrombin protein in your blood:

  • Type I (Quantitative): Your body doesn’t produce enough antithrombin protein. Both the antigen level (the amount of protein) and the functional activity (how well it works) will be low [5][6]. This is generally considered the more severe form [7].
  • Type II (Qualitative): You have a normal amount of antithrombin protein, but the protein itself has a structural flaw that prevents it from working correctly [5]. This is further broken down into:
    • Reactive Site (RS) defects: The protein can’t “grab” the clotting factors to stop them [8].
    • Heparin Binding Site (HBS) defects: The protein can’t connect with heparin, which it needs to work at full speed [9].
    • Pleiotropic Effect: A complex defect affecting both the structure and function [8].

The “Heparin Trap” and Resistance

A unique challenge of this condition is a phenomenon called heparin resistance. Standard heparin (and Low Molecular Weight Heparin, like Lovenox) works by attaching to antithrombin to speed up its “braking” action by 1,000 times [10][11].

If you have very low levels of antithrombin, heparin has nothing to attach to. This means that in an emergency, standard doses of heparin may not stop a clot from growing [10]. In these cases, doctors must either give you antithrombin concentrate to provide the missing protein or use alternative medications like Direct Oral Anticoagulants (DOACs) or Argatroban, which do not require antithrombin to work [12][11][13].

How the Diagnosis is Confirmed

Getting an accurate diagnosis requires careful timing and specific tests, as current medications can “hide” the deficiency or cause a false positive [14][15].

  1. Functional Activity Assay: This is usually the first test. It measures how well your antithrombin can stop clotting factors in a lab setting [9].
  2. Antigen Test: If activity is low, this test measures the total amount of protein to see if you have Type I or Type II [5].
  3. Genetic Sequencing: Because some Type II mutations can look “normal” on basic functional tests, sequencing the SERPINC1 gene is the gold standard for confirming the diagnosis and identifying the specific subtype [16][17].

Important Note on Testing: If you are currently taking a DOAC (like Xarelto or Eliquis) or heparin, these drugs can interfere with lab results, often making it look like you have a deficiency when you don’t, or vice versa [18][14]. For the most accurate results, testing should ideally be done when you are not taking these medications, or special “neutralizers” must be used in the lab [15].

Frequently Asked Questions

What is the difference between Type I and Type II antithrombin deficiency?
Type I means your body does not produce enough of the antithrombin protein, which is generally considered the more severe form. Type II means you have a normal amount of the protein, but a structural flaw prevents it from working correctly to stop blood clots.
Can I be tested for antithrombin deficiency while taking blood thinners?
Testing while taking blood thinners like heparin or DOACs can interfere with your lab results and cause false readings. Your doctor may recommend testing when you are not taking these medications or using special lab techniques to get an accurate result.
What is heparin resistance?
Heparin is a common blood thinner that needs the antithrombin protein to work properly. If your antithrombin levels are very low, standard heparin may not be effective at stopping a blood clot, requiring doctors to use alternative medications like DOACs or Argatroban.
How is congenital antithrombin deficiency diagnosed?
Doctors typically start with a functional activity assay to see how well your antithrombin works, followed by an antigen test to measure protein levels. Genetic sequencing of the SERPINC1 gene is the gold standard used to confirm the diagnosis and the specific subtype.

Questions for Your Doctor

  • • Does my lab report show a Type I (quantitative) or Type II (qualitative) deficiency?
  • • If I have Type II deficiency, is it the Heparin Binding Site (HBS) subtype or the Reactive Site (RS) subtype?
  • • Were my tests taken while I was on heparin or a DOAC (like Eliquis or Xarelto)? How might that have affected the results?
  • • Is my antithrombin activity level low enough that I should expect 'heparin resistance' if I ever need emergency treatment?
  • • Do we need to perform genetic sequencing of the SERPINC1 gene to confirm my specific mutation?

Questions for You

  • • Am I currently taking any 'blood thinners' that I should mention to the lab technician before my next blood draw?
  • • Has anyone in my family been diagnosed with 'Antithrombin III' deficiency specifically, rather than just 'a blood clotting disorder'?
  • • How do I feel about the possibility of needing a different type of medication if standard heparin doesn't work for me?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    SerpinC1/Antithrombin III in kidney-related diseases.

    Lu Z, Wang F, Liang M

    Clinical science (London, England : 1979) 2017; (131(9)):823-831 doi:10.1042/CS20160669.

    PMID: 28424376
  2. 2

    A pyruvylated and sulfated galactan from the green alga Dictyosphaeria cavernosa: Structure, anticoagulant property and inhibitory effect on zebrafish thrombosis.

    Yang Y, Qin L, Lu X, et al.

    Carbohydrate polymers 2024; (324()):121492 doi:10.1016/j.carbpol.2023.121492.

    PMID: 37985046
  3. 3

    Atypical pulmonary thromboembolism caused by the mutation site SERPINC1 of the antithrombin III gene: A case report.

    Lin M, Sun X, Wu J

    Medicine 2024; (103(31)):e39175 doi:10.1097/MD.0000000000039175.

    PMID: 39093784
  4. 4

    Antithrombin III deficiency in a patient with recurrent venous thromboembolism: A case report.

    Luo JQ, Mao SS, Chen JY, et al.

    World journal of clinical cases 2023; (11(20)):4956-4960 doi:10.12998/wjcc.v11.i20.4956.

    PMID: 37583989
  5. 5

    Exploring antithrombin: insights into its physiological features, clinical implications and analytical techniques.

    Saboor M, Hamali HA, Mobarki AA, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2024; (35(2)):43-48 doi:10.1097/MBC.0000000000001271.

    PMID: 38179715
  6. 6

    SERPINC1 variants causing hereditary antithrombin deficiency in a Danish population.

    Kjaergaard AD, Larsen OH, Hvas AM, Nissen PH

    Thrombosis research 2019; (175()):68-75 doi:10.1016/j.thromres.2019.01.022.

    PMID: 30721820
  7. 7

    How we treat severe inherited antithrombin deficiency: lessons from cases homozygous for the Budapest 3 variant.

    Bravo-Pérez C, Corral J, Orlando C, et al.

    Journal of thrombosis and haemostasis : JTH 2025; (23(5)):1648-1656 doi:10.1016/j.jtha.2025.01.015.

    PMID: 39933654
  8. 8

    SERPINC1 gene mutations in antithrombin deficiency.

    Mulder R, Croles FN, Mulder AB, et al.

    British journal of haematology 2017; (178(2)):279-285 doi:10.1111/bjh.14658.

    PMID: 28317092
  9. 9

    Diagnostic Performance of Commercial Antithrombin Activity Assays: Do We Get What We Expect?

    Orlando C, Drèze C, Evenepoel A, et al.

    Thrombosis and haemostasis 2025; doi:10.1055/a-2628-4046.

    PMID: 40473262
  10. 10

    Antithrombin Deficiency in Trauma and Surgical Critical Care.

    Ehrhardt JD, Boneva D, McKenney M, Elkbuli A

    The Journal of surgical research 2020; (256()):536-542 doi:10.1016/j.jss.2020.07.010.

    PMID: 32799002
  11. 11

    Heparin Resistance and Anticoagulation Failure in a Challenging Case of Cerebral Venous Sinus Thrombosis.

    King AB, O'Duffy AE, Kumar AB

    The Neurohospitalist 2016; (6(3)):118-21 doi:10.1177/1941874415591500.

    PMID: 27366296
  12. 12

    Successful treatment of a massive pulmonary embolism using rivaroxaban in a patient with antithrombin III deficiency.

    Yamaguchi J, Hara N, Yamaguchi T, et al.

    Journal of cardiology cases 2017; (16(5)):144-147 doi:10.1016/j.jccase.2017.06.008.

    PMID: 30279820
  13. 13

    Heparin-resistant Thrombosis Due to Homozygous Antithrombin Deficiency Treated With Rivaroxaban: A Case Report.

    Van Bruwaene L, Huisman A, Urbanus RT, Versluys B

    Journal of pediatric hematology/oncology 2016; (38(8)):658-660 doi:10.1097/MPH.0000000000000608.

    PMID: 27322714
  14. 14

    Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.

    Eller T, Flieder T, Fox V, et al.

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2017; (51(4)):624-632 doi:10.1093/ejcts/ezw368.

    PMID: 28043992
  15. 15

    Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants.

    Favaloro EJ, Pasalic L

    Research and practice in thrombosis and haemostasis 2022; (6(2)):e12676 doi:10.1002/rth2.12676.

    PMID: 35316943
  16. 16

    Incidence and features of thrombosis in children with inherited antithrombin deficiency.

    de la Morena-Barrio B, Orlando C, de la Morena-Barrio ME, et al.

    Haematologica 2019; (104(12)):2512-2518 doi:10.3324/haematol.2018.210666.

    PMID: 30975910
  17. 17

    Case report: A case of new mutation in SERPINC1 leading to thrombotic microangiopathy.

    Li B, Zhang X, Lv H, et al.

    Frontiers in genetics 2023; (14()):1278511 doi:10.3389/fgene.2023.1278511.

    PMID: 37829283
  18. 18

    Transitioning of Patients from Direct-Acting Oral Anticoagulant to Heparin: Impact on Laboratory Testing.

    Arachchillage DJ, Vinayagam S, Parsons A, et al.

    Seminars in thrombosis and hemostasis 2025; doi:10.1055/a-2734-2293.

    PMID: 41232561

This page explains the biology and diagnosis of congenital antithrombin deficiency for educational purposes. Always consult your hematologist before stopping medications or interpreting your lab results.

Stay up to date

Get notified when new research about Hereditary thrombophilia due to congenital antithrombin deficiency is published.

No spam. Unsubscribe anytime.